Skip to main content
Log in

Evidence for the use of cannabinoids in Parkinson’s disease

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Cannabis and synthetic cannabinoid formulations have now been legally approved in several countries for treatment of patients with Parkinson’s disease (PD). Hence, PD patients consult physicians more frequently for prescription of cannabinoids to alleviate symptoms that might not respond well to dopaminergic treatment. Despite the increasing volume of research generated in the field of cannabinoids and their effect on Parkinson’s disease, there is still paucity of sufficient clinical data about the efficacy and safety in PD patients. There is increasing understanding of the endocannabinoid system, and the distribution of cannabinoid receptors in basal ganglia structures might suggest potential benefit on parkinsonian symptoms. Concerning clinical research, only one of to date four conducted randomized placebo-controlled trials showed an effect on motor symptoms with alleviation of levodopa-induced dyskinesia. There are a growing number of uncontrolled trials and case reports that suggest beneficial effects of cannabinoids in PD patients. However, the variety of substances investigated, the varying routes of intake, differing doses and time courses make it difficult to compare data. We here provide an overview of the current literature in this field and discuss a pragmatic approach for the clinical use of cannabinoids in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ablin J, Ste-Marie PA, Schafer M, Hauser W, Fitzcharles MA (2016) Medical use of cannabis products: lessons to be learned from Israel and Canada. Schmerz 30:3–13

    Article  CAS  PubMed  Google Scholar 

  • Aronow WS, Cassidy J (1974) Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med 291:65–67

    Article  CAS  PubMed  Google Scholar 

  • Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649

    Article  PubMed  Google Scholar 

  • Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP (2004) Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63:1245–1250

    Article  CAS  PubMed  Google Scholar 

  • Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP (2012) Delta(9)-tetrahydrocannabinol (Delta(9)-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson’s disease. Neuropathol Appl Neurobiol 38:535–547

    Article  CAS  PubMed  Google Scholar 

  • Centonze D, Rossi S, Prosperetti C, Gasperi V, De CV, Bari M, Tscherter A, Febbraro F, Bernardi G, Maccarrone M (2007) Endocannabinoids limit metabotropic glutamate 5 receptor-mediated synaptic inhibition of striatal principal neurons. Mol Cell Neurosci 35:302–310

    Article  CAS  PubMed  Google Scholar 

  • Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA (2014a) Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther 39:564–566

    Article  CAS  PubMed  Google Scholar 

  • Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos AC, Teixeira AL, Hallak JE, Crippa JA (2014b) Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol 28:1088–1098

    Article  CAS  PubMed  Google Scholar 

  • Chang A, Fox SH (2016) Psychosis in Parkinson’s disease: epidemiology, pathophysiology, and management. Drugs 76:1093–1118

    Article  CAS  PubMed  Google Scholar 

  • Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534–551

    Article  CAS  PubMed  Google Scholar 

  • Covey DP, Mateo Y, Sulzer D, Cheer JF, Lovinger DM (2017) Endocannabinoid modulation of dopamine neurotransmission. Neuropharmacology 124:52–61

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease. FASEB J 14:1432–1438

    PubMed  Google Scholar 

  • ElSohly M, Gul W (2014) Constituents of Cannabis sativa. In: Pertwee RG (ed) Handbook of cannabis. Oxford University Press, New York, p 1093

    Google Scholar 

  • Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE (2018) Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol 84:797–811

    Article  PubMed  Google Scholar 

  • Fernandez-Espejo E, Caraballo I, Rodriguez DF, Ferrer B, El Banoua F, Flores JA, Galan-Rodriguez B (2004) Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function. Neuropsychopharmacology 29:1134–1142

    Article  CAS  PubMed  Google Scholar 

  • Fernandez-Ruiz J (2009) The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 156:1029–1040

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fernandez-Ruiz J, Garcia C, Sagredo O, Gomez-Ruiz M, de Lago E (2010a) The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 14:387–404

    Article  CAS  PubMed  Google Scholar 

  • Fernandez-Ruiz J, Hernandez M, Ramos JA (2010b) Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:e72–e91

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fernandez-Ruiz J, Moreno-Martet M, Rodriguez-Cueto C, Palomo-Garo C, Gomez-Canas M, Valdeolivas S, Guaza C, Romero J, Guzman M, Mechoulam R, Ramos JA (2011) Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 163:1365–1378

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fox SH, Henry B, Hill M, Crossman A, Brotchie J (2002) Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease. Mov Disord 17:1180–1187

    Article  PubMed  Google Scholar 

  • Frankel JP, Hughes A, Lees AJ, Stern GM (1990) Marijuana for Parkinsonian tremor. J Neurol Neurosurg Psychiatry 53:436

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gandor F, Ebersbach G (2017) Cannabinoids in the treatment of Parkinson’s disease. Neurol Int Open 1:307–311

    Article  Google Scholar 

  • Garcia MC, Cinquina V, Palomo-Garo C, Rabano A, Fernandez-Ruiz J (2015) Identification of CB(2) receptors in human nigral neurons that degenerate in Parkinson’s disease. Neurosci Lett 587:1–4

    Article  CAS  PubMed  Google Scholar 

  • Garcia-Arencibia M, Gonzalez S, de Lago E, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134:162–170

    Article  CAS  PubMed  Google Scholar 

  • Garriott JC, King LJ, Forney RB, Hughes FW (1967) Effects of some tetrahydrocannabinols on hexobarbital sleeping time and amphetamine induced hyperactivity in mice. Life Sci 6:2119–2128

    Article  CAS  PubMed  Google Scholar 

  • Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423–428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Giuffrida R, Vingerhoets FJ, Bogousslavsky J, Ghika J (2005) Pain in Parkinson’s disease. Rev Neurol (Paris) 161:407–418

    Article  CAS  Google Scholar 

  • Gomez-Galvez Y, Palomo-Garo C, Fernandez-Ruiz J, Garcia C (2016) Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 64:200–208

    Article  CAS  PubMed  Google Scholar 

  • Grotenhermen F, Muller-Vahl K (2012) The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 109:495–501

    PubMed  PubMed Central  Google Scholar 

  • Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agro A, Maccarrone M (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22:6900–6907

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Health Canada (2013) Information for health care professionals—Cannabis (marihuana, marijuana) and the cannabinoids. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf. Accessed 13 May 2017

  • Herkenham M, Lynn AB, De Costa BR, Richfield EK (1991) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547:267–274

    Article  CAS  PubMed  Google Scholar 

  • Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, Pawlostky JM, Lotersztajn S, Mallat A (2008) Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 134:432–439

    Article  PubMed  Google Scholar 

  • Howes J, Osgood P (1974) The effect of delta9-tetrahydrocannabinol on the uptake and release of 14C-dopamine from crude striatal synaptosoma; preparations. Neuropharmacology 13:1109–1114

    Article  CAS  PubMed  Google Scholar 

  • Izzo AA, Borrelli F, Capasso R, Di Vincenzo M, Mechoulam R (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515–527

    Article  CAS  PubMed  Google Scholar 

  • Jouanjus E, Lapeyre-Mestre M, Micallef J (2014) Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc 3:e000638

    Article  PubMed  PubMed Central  Google Scholar 

  • Julian MD, Martin AB, Cuellar B, Rodriguez DF, Navarro M, Moratalla R, Garcia-Segura LM (2003) Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 119:309–318

    Article  CAS  PubMed  Google Scholar 

  • Kelsey JE, Harris O, Cassin J (2009) The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson’s disease. Behav Brain Res 203:304–307

    Article  CAS  PubMed  Google Scholar 

  • Kindred JH, Li K, Ketelhut NB, Proessl F, Fling BW, Honce JM, Shaffer WR, Rudroff T (2017) Cannabis use in people with Parkinson’s disease and multiple sclerosis: a web-based investigation. Complement Ther Med 33:99–104

    Article  PubMed  Google Scholar 

  • Klein TW (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5:400–411

    Article  CAS  PubMed  Google Scholar 

  • Kreitzer AC, Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models. Nature 445:643–647

    Article  CAS  PubMed  Google Scholar 

  • Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790–4805

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernandez-Ruiz JJ (2001) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson’s syndrome and of MPTP-treated marmosets. Eur J Neurosci 14:1827–1832

    Article  CAS  PubMed  Google Scholar 

  • Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol Dis 19:96–107

    Article  CAS  PubMed  Google Scholar 

  • Lotan I, Treves TA, Roditi Y, Djaldetti R (2014) Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol 37:41–44

    Article  PubMed  Google Scholar 

  • Maccarrone M, Gubellini P, Bari M, Picconi B, Battista N, Centonze D, Bernardi G, Finazzi-Agro A, Calabresi P (2003) Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 85:1018–1025

    Article  CAS  PubMed  Google Scholar 

  • Mainka T, Stork J, Hidding U, Buhmann C (2018) Cannabis in Parkinson’s disease: hype or help? Fortschr Neurol Psychiatr 86:106–116

    Article  PubMed  Google Scholar 

  • Malek N, Grosset DG (2015) Medication adherence in patients with Parkinson’s disease. CNS Drugs 29:47–53

    Article  CAS  PubMed  Google Scholar 

  • Martinez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Vera C, Oyarzabal J, Canela EI, Lanciego JL, Nadal X, Navarro G, Borea PA, Franco R (2017) Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front Pharmacol 8:744

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meschler JP, Howlett AC, Madras BK (2001) Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology 156:79–85

    Article  CAS  PubMed  Google Scholar 

  • Mesnage V, Houeto JL, Bonnet AM, Clavier I, Arnulf I, Cattelin F, Le Fur G, Damier P, Welter ML, Agid Y (2004) Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol 27:108–110

    Article  CAS  PubMed  Google Scholar 

  • Mezey E, Toth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, Guo A, Blumberg PM, Szallasi A (2000) Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 97:3655–3660

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE (2001) Triggering myocardial infarction by marijuana. Circulation 103:2805–2809

    Article  CAS  PubMed  Google Scholar 

  • Navarro G, Reyes-Resina I, Rivas-Santisteban R, Sanchez DMV, Morales P, Casano S, Ferreiro-Vera C, Lillo A, Aguinaga D, Jagerovic N, Nadal X, Franco R (2018) Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes. Biochem Pharmacol 157:148–158

    Article  CAS  PubMed  Google Scholar 

  • Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215

    Article  CAS  PubMed  Google Scholar 

  • Pertwee RG, Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66:101–121

    Article  CAS  PubMed  Google Scholar 

  • Pezzella FR, Colosimo C, Vanacore N, Di Rezze S, Chianese M, Fabbrini G, Meco G (2005) Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease. Mov Disord 20:77–81

    Article  PubMed  Google Scholar 

  • Prakash R, Aronow WS, Warren M, Laverty W, Gottschalk LA (1975) Effects of marihuana and placebo marihuana smoking on hemodynamics in coronary disease. Clin Pharmacol Ther 18:90–95

    Article  CAS  PubMed  Google Scholar 

  • Pratt-Hyatt M, Zhang H, Snider NT, Hollenberg PF (2010) Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118 V) on the metabolism of anandamide. Drug Metab Dispos 38:2075–2082

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, Strong R, Lutz B, Marsicano G, Roberts JL, Giuffrida A (2009) WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Eur J Neurosci 29:2177–2186

    Article  PubMed  PubMed Central  Google Scholar 

  • Roland CL, Lake J, Oderda GM (2016) Prevalence of prescription opioid misuse/abuse as determined by international classification of diseases codes: a systematic review. J Pain Palliat Care Pharmacother 30:258–268

    Article  PubMed  Google Scholar 

  • Sanudo-Pena MC, Walker JM (1997) Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 77:1635–1638

    Article  CAS  PubMed  Google Scholar 

  • Sidney S (2002) Cardiovascular consequences of marijuana use. J Clin Pharmacol 42:64S–70S

    Article  CAS  PubMed  Google Scholar 

  • Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology 57:2108–2111

    Article  CAS  PubMed  Google Scholar 

  • Sierra S, Luquin N, Rico AJ, Gomez-Bautista V, Roda E, Dopeso-Reyes IG, Vazquez A, Martinez-Pinilla E, Labandeira-Garcia JL, Franco R, Lanciego JL (2015) Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct 220:2721–2738

    Article  CAS  PubMed  Google Scholar 

  • Stampanoni BM, Sancesario A, Morace R, Centonze D, Iezzi E (2017) Cannabinoids in Parkinson’s disease. Cannabis Cannabinoid Res 2:21–29

    Article  CAS  Google Scholar 

  • Starowicz K, Nigam S, Di Vincenzo M (2007) Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114:13–33

    Article  CAS  PubMed  Google Scholar 

  • The American College of Obstetricians and Gynecologists Committee (2015) No. 637. Marijuana use during pregnancy and lactation. Obstet Gynecol 126:234–238

    Article  Google Scholar 

  • van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480:133–150

    Article  CAS  PubMed  Google Scholar 

  • van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM (2005) A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson’s disease. FASEB J 19:1140–1142

    Article  CAS  PubMed  Google Scholar 

  • van Vliet SA, Vanwersch RA, Jongsma MJ, Olivier B, Philippens IH (2008) Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model. Eur Neuropsychopharmacol 18:383–389

    Article  CAS  PubMed  Google Scholar 

  • Venderova K, Ruzicka E, Vorisek V, Visnovsky P (2004) Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms. Mov Disord 19:1102–1106

    Article  PubMed  Google Scholar 

  • Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313:2456–2473

    Article  CAS  PubMed  Google Scholar 

  • Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, Dursun SM, Tumas V (2009) Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol 23:979–983

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carsten Buhmann.

Ethics declarations

Conflicts of interest

Prof. Carsten Buhmann, MD: fees for advisory board participation: UCB Pharma, Zambon. Lecture fees: AbbVie Pharma, BIAL Pharma, Desitin, GE Healthcare, Grünenthal Pharma, Licher GmbH, Medtronic, Novartis, TAD Pharma, UCB Pharma, Zambon Pharma; Dr. Tina Mainka: royalties: Urban Fischer in Elsevier Verlag. Honoraria for lectures: GE Healthcare. Dr. Florin Gandor, MD: fees for advisory board participation: AbbVie Pharma. Lecture fees: MERZ Pharma, BIAL Pharma; Prof. Georg Ebersbach, MD: consultancy fees: AOK Nordost. Fees for advisory board participation: AbbVie Pharma, Grünenthal Pharma, Neuroderm Inc., Stada Pharma, Neurocrine Inc. Lecture fees: AbbVie Pharma, BIAL Pharma, Britannia Pharma, Desitin Pharma, Licher GmbH, UCB Pharma, Zambon Pharma, royalties: Kohlhammer Verlag, Thieme Verlag.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buhmann, C., Mainka, T., Ebersbach, G. et al. Evidence for the use of cannabinoids in Parkinson’s disease. J Neural Transm 126, 913–924 (2019). https://doi.org/10.1007/s00702-019-02018-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-019-02018-8

Keywords

Navigation